Journal
DRUGS OF THE FUTURE
Volume 44, Issue 8, Pages 635-642Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2019.44.8.3024184
Keywords
Rimegepant; BHV-3000; BMS-927711; Migraine; CGRP; CGRP receptor antagonist; Gepants
Categories
Funding
- Allergan
- Eli Lilly
- Novartis
- Teva
Ask authors/readers for more resources
Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under development by Biohaven Pharmaceuticals for the acute and preventive treatment of migraine. Among patients with acute migraine, significant clinical efficacy has been reported with a rimegepant single dose. The completed pivotal phase II and III trials showed a beneficial action of rimegepant in terms of pain freedom, pain relief, release of migraine symptoms and lifestyle recovery. Moreover, adverse events were mild or moderate and did not cause trial discontinuation. Several clinical trials are currently ongoing to evaluate long-term safety and efficacy profiles in patients with migraine and refractory trigeminal neuralgia. Drug-drug interactions potentially affecting rimegepant pharmacokinetics should be assessed in future clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available